AI pharmaceutical trend is obvious! What are the possibilities besides improving R & D Efficiency

[pharmaceutical network market analysis] in recent years, artificial intelligence technology has been more and more used in biomedicine and other aspects The combination of biomedicine and artificial intelligence technology has also brought many new breakthroughs, especially in the field of pharmaceutical research and development In this case, AI pharmaceutical is coming to a head in the pharmaceutical industry A few days ago, Jingtai technology, an AI pharmaceutical company, completed a round B financing of about 15 million US dollars Later, Roche, a pharmaceutical giant, purchased all shares of flatiron health, a big data company of cancer, for 1.9 billion US dollars, actively distributed digital and AI In fact, new drug research and development cycle is long, investment is large, lasting for a long time, and efficiency is low, which has always been a "serious problem" in the field of medicine According to the data of a research center, it takes about 96.8 months for a new drug to go on the market from drug discovery to FDA approval In terms of cost, there are data showing that since 2010, the approved drug development cost of 12 major pharmaceutical companies has increased by 33%, about 1.6 billion US dollars per year With the addition of AI, these problems have seen gratifying changes According to techenergy's research report, AI can increase the success rate of new drug research and development from 12% to 14% The only 2% growth can not be underestimated It can save billions of dollars for the whole biopharmaceutical industry, and at the same time, it can save a lot of research and development time What can ta do besides improve the efficiency of drug research and development? In fact, drug companies are concerned about the cost and R & D issues when developing new drugs For example, can they shorten the R & D time of new drugs? Can help enterprises save labor costs? Can risks be reduced, etc? These problems, "Ai" pharmaceutical has begun to bring surprises AI pharmaceutical enterprise personnel once said that through AI calculation and prediction, it can help pharmaceutical enterprises prioritize drug compounds, crystal type candidates and R & D routes that are easy to succeed, thus reducing R & D time and trial and error range In particular, the research and development cycle of crystal form will be shortened from several months or even one year to several weeks and months This also means that AI can reduce the error rate of new drug research and development, improve the success rate, shorten the research and development time, and bring better benefits to enterprises In addition, there have been many people do not trust traditional Chinese medicine, because most traditional Chinese medicine can not indicate the specific molecular pharmacological mechanism and side effects If AI drug discovery technology can be used in traditional Chinese medicine research, it will accelerate the development of traditional Chinese medicine For example, AI, through in-depth learning, builds neural networks, absorbs all known single-step organic chemical reactions, deconstructs molecules in drugs, and separates all chemicals Through chemical reactions and clinical data, it finds the effective chemicals, and analyzes other chemicals one by one If it can be realized, it will play an important role in promoting the development of traditional Chinese medicine In fact, if AI pharmaceutical can become the general trend, it may also play a role in reducing drug prices in the future This will further reduce the burden of drug use and provide patients with more choice of high-quality drugs On the one hand, pharmaceutical companies do not have to transfer costs to patients because of too many R & D failures On the other hand, "Ai pharmaceutical" can improve the speed of new drug market and further balance the R & D costs At present, with the development of artificial intelligence, it can be predicted that in the future, whether in new drug research and development or other fields, the prospect of AI pharmaceutical is very broad, but at the same time, you should also see that the current AI pharmaceutical industry is still in the early stage of development, there are still a lot of difficulties to break through, and the large-scale application of related products will take a long time In addition, the pharmaceutical industry has always been one of the industries strictly regulated by the state, which is a typical policy driven industry Therefore, in the process of AI pharmaceutical, we need to pay more attention to national policies and make changes at any time.